Overview

Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations Independent of HER2 Expression With Progression After Previous Treatment

Status:
Not yet recruiting

Trial end date:
2024-11-09

Target enrollment:

Participant gender:

Summary

This Clinical Trial is investigating the potential efficacy of axitinib after genetic testing in BRCA 1/2 Mutation patients, regardless of HER2 expression, who have progressed after at least one line of standard treatment or for whom there is no consensus treatment approach. The use of Axitinib may help physicians plan for more effective patient care in combination with existing treatment protocols.

Phase:

Phase 1

Details

Lead Sponsor:

Lynkcell Europe

Treatments:

Axitinib